Sign in
THTX Stock Price, Chart, Stats & News
Theratechnologies Inc.
Save
155.87M
Market cap
–
Current P/E
55.87x
Forward P/E
THTX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 76.89% |
Operating margin | 1.47% |
Pretax margin | -17.28% |
Net margin | -19.83% |
Effective tax rate | -14.75% |
ROA | -23.89% |
ROE | 47.31% |
D/E | -1.56x |
Interest coverage ratio | 0.19x |
THTX valuation
P/E | – |
P/S | 2.52x |
P/B | -5.99x |
P/CF | 68.81x |
P/FCF | -20.30x |
P/OCF | 68.81x |
PEG | 0.08x |
EV multiple | -26.63x |
About
Theratechnologies Inc. is a biopharmaceutical firm dedicated to creating and marketing a range of treatments aimed at fulfilling critical medical requirements across the United States, Canada, and Europe. Its current product portfolio includes EGRIFTA and EGRIFTA SV, designed to diminish excessive abdominal fat in HIV-positive individuals experiencing lipodystrophy. Additionally, it markets Trogarzo, an injectable formulation of ibalizumab, which targets multidrug-resistant HIV-1 infections.
Similar securities
Based on sector and market capitalization
Report issue